Format

Send to

Choose Destination
Neurology. 1999 Oct 22;53(7):1588-9.

Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis.

Author information

1
Department of Neurological Sciences, Università La Sapienza, Rome, Italy.

Abstract

We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.

PMID:
10534275
DOI:
10.1212/wnl.53.7.1588
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center